GC Medical Science Corporation (142280) Fair Value & Analysis
Healthcare · KR · Market cap 59.8B KRW
Fair value as of: Jul 20, 2026
From 25 valuation models · updated 21 days ago
Fair value updated Jul 20, 2026, revised from 2,751 KRW to 2,730 KRW (−0.8%) since Jul 7, 2026. Share price +3.0% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (1,755 KRW to 3,583 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 2,395 KRW – 12,900 KRW · fair‑value band 1,755 KRW – 3,583 KRW · the 2,900 KRW price screens above the 2,730 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
GC Medical Science Corporation (142280) currently trades at 2,900 KRW, while our model-based Fair Value estimate is 2,730 KRW, implying the stock looks roughly 5.9% fairly valued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, GC Medical Science Corporation generated revenue of 105B KRW at a net margin of 4.2%. Revenue declined 11.1% year over year. It earns a return on equity of 9.9%. Net debt stands at 10.2B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 1,755 KRW (bear case) to 3,583 KRW (bull case); at 2,900 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -6%, 142280 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (2,912 KRW) versus Dividend Discount (288.53 KRW). Highest evidence: Growth DCF (80).
Notify me when 142280 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases.
Full company description
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol. The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and " GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo. Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis. The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GC Medical Science Corporation reported revenue of 108B KRW in FY2025 versus 102B KRW in FY2021, a compound +1.6%/yr. Reported net income was 3.7B KRW in FY2025.
Watch 142280: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare GC Medical Science Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GC Medical Science Corporation (142280) overvalued or undervalued?
What is the fair value of 142280?
What is the quality score of 142280?
What is the revenue of GC Medical Science Corporation (142280)?
What is the net profit margin of 142280?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GC Medical Science Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.